The bottom line: No single ranking captures the full picture of a healthcare system. The WHO's 2000 report (the last comprehensive global ranking) measured certain dimensions; other frameworks prioritize different metrics. This scorecard evaluates 15 countries across six dimensions that matter most to real patients: cost, access, outcomes, patient satisfaction, innovation, and equity. The results challenge assumptions about which countries deliver the best healthcare — and which deliver the best value.
The Scorecard Methodology
Each country is scored 1–10 across six equally weighted dimensions, using the most recent available data from WHO, OECD, Commonwealth Fund, JCI, national health statistics agencies, and peer-reviewed research. The composite score (out of 60) represents a balanced view of system performance rather than any single metric. No weighting system is perfect — a country that scores 10 in innovation and 3 in equity produces a very different patient experience than one scoring 7 in both. The composite is a starting point for analysis, not a definitive verdict.
The 2026 Global Healthcare Scorecard
| Country | Cost (Value) | Access | Outcomes | Satisfaction | Innovation | Equity | Composite |
|---|---|---|---|---|---|---|---|
| Norway | 7 | 8 | 9 | 8 | 7 | 9 | 48 |
| Netherlands | 7 | 9 | 9 | 8 | 7 | 8 | 48 |
| Switzerland | 5 | 9 | 9 | 9 | 8 | 7 | 47 |
| Australia | 7 | 8 | 9 | 8 | 7 | 8 | 47 |
| Germany | 6 | 8 | 8 | 7 | 8 | 8 | 45 |
| Japan | 7 | 8 | 10 | 7 | 8 | 7 | 47 |
| France | 7 | 8 | 8 | 7 | 7 | 8 | 45 |
| UK | 8 | 6 | 8 | 6 | 7 | 8 | 43 |
| Canada | 7 | 5 | 8 | 6 | 7 | 7 | 40 |
| South Korea | 7 | 8 | 9 | 7 | 8 | 7 | 46 |
| Colombia | 9 | 7 | 7 | 8 | 5 | 5 | 41 |
| United States | 2 | 6 | 7 | 6 | 10 | 3 | 34 |
| Thailand | 8 | 6 | 7 | 8 | 5 | 5 | 39 |
| Turkey | 8 | 7 | 6 | 7 | 5 | 5 | 38 |
| Mexico | 7 | 5 | 6 | 6 | 4 | 4 | 32 |
The US Paradox: Innovation Leader, Value Laggard
The United States scores a perfect 10 in innovation — it leads the world in pharmaceutical development, medical device engineering, biomedical research, and clinical trial infrastructure. No other country comes close in raw R&D output. But this innovation score is accompanied by the lowest cost-value score (2/10) and the lowest equity score (3/10) among all 15 countries evaluated.
The US spends $13,493 per capita — far more than any other nation — yet achieves outcomes (life expectancy, maternal mortality, chronic disease management) that lag behind countries spending half as much. The innovation that emerges from US spending is available globally, but the cost of accessing it domestically is uniquely punishing.
The equity score reflects the reality that access to quality healthcare in the US depends more heavily on income, employment status, and geography than in any other developed nation. The uninsured (28+ million), the underinsured (estimated 43 million), and those living in healthcare deserts face a fundamentally different system than those with premium employer-sponsored coverage.
Colombia's Composite Position
Colombia's composite score of 41/60 places it ahead of the United States (34/60) on this scorecard — a result that surprises many Americans but makes sense when you examine the dimensions. Colombia scores highest on cost-value (9/10), reflecting dramatically lower prices for comparable quality care at top-tier private facilities. Patient satisfaction scores well (8/10), driven by personal attention, transparent pricing, and a care culture that prioritizes the patient relationship.
Colombia's lower scores in innovation (5/10) and equity (5/10) reflect legitimate limitations. Colombia is not a global R&D leader, and its public healthcare system (EPS) faces access and quality challenges, particularly in rural areas. The scorecard accurately captures both Colombia's strengths and its gaps.
For Americans considering medical tourism, the most relevant comparison is not Colombia's overall system vs. the US overall system. It's Colombia's private, JCI-accredited tier vs. the US experience for a self-pay or high-deductible patient. In that specific comparison — a specific patient, a specific procedure, a specific facility — Colombia's cost-value and access scores are even more favorable, because the medical tourism patient accesses Colombia's best facilities without the equity limitations that affect the broader population.
Dimension by Dimension
Cost (Value)
Evaluates what patients get for what they pay. Countries with universal coverage and low out-of-pocket costs score high. The US, with the world's highest spending and disproportionately modest outcomes, scores lowest. Colombia scores highest among non-universal systems because its private sector delivers quality care at prices that reflect actual costs rather than US-style inflated pricing.
Access
Measures how easily patients can reach care: wait times, geographic availability, administrative barriers, and appointment availability. Netherlands and Switzerland lead with rapid access. Canada and the UK lose points for long wait times. The US loses points for prior authorization barriers and coverage-dependent access.
Outcomes
Life expectancy, infant mortality, maternal mortality, chronic disease management, surgical success rates. Japan leads (life expectancy 84.8 years). The US underperforms relative to spending (life expectancy 77.5 years, highest maternal mortality among developed nations).
Patient Satisfaction
Self-reported experience with the healthcare system. Switzerland and Colombia's private sector score highest. UK and Canada lose points for wait-time dissatisfaction.
Innovation
R&D spending, new drug approvals, clinical trial activity, medical device development. The US dominates. South Korea, Japan, Germany, and Switzerland also score well.
Equity
How equally healthcare access and outcomes are distributed across income levels, geography, and demographics. Nordic countries and universal-coverage systems lead. The US and developing nations trail.
This scorecard is editorial — it synthesizes publicly available data into a structured framework for comparison, but reasonable people can disagree on dimension weights, scoring criteria, and data interpretation. The WHO's 2000 report (the last comprehensive global ranking) used different methodology and produced different results (Colombia #22, US #37, France #1). No single scorecard captures the full complexity of a national healthcare system. Use this as one input among many when evaluating your own healthcare options.
See How Colombia's Best Compares to Your Options
JCI-accredited facilities, credentialed specialists, transparent pricing. Discover why Colombia scores high where it matters most for patients.
Request a Free Consultation